Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0777 vs Lorazepam in GAD
NCT00546624Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tpa-023 in generalized anxiety disorder (GAD), sponsored by Merck & Co.. Started Nov 2002; status: completed.
02
Drugs
tpa-023
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00546624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546624.